OHSU

IRB #

IRB00007711

Title

An open-label multicenter study of Sipuleucel-T in metastatic castrate resistant prostate cancer patients previously treated with Sipuleucel-T on Dendreon study P-11

Principal Investigator

Tomasz Beer

Study Purpose

To examine the immune response of subjects who were previously treated with sipuleucel-T (Provenge). Also to assess the safety of receiving 3 additional infusions of sipuleucel-T and the correlation between immune response and overall survival.

Medical Condition(s)

Prostate cancer

Eligibility Criteria

- Participated in the Dendreon P11 trial and received at least one infusion of sipuleucel-T
- Must have advanced prostate cancer that has spread outside the prostate
- Subjects must be castrate and cancer must be progressing by PSA or scans

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

12 months, and then phone calls every 6 months for survival

Minors Included

No

Contact

Clinical trials Information Line: Phone 503-494-1080 or trials@ohsu.edu

Sponsor

Dendreon

Recruitment End

Compensation Provided

No


Go Back